secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001628280-24-019986
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M
--------------------------------------------------------------------------------

- Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).
- Net loss $26.5M ($0.11/sh) vs $26.8M ($0.13/sh) in Q1 2023; cash & investments $202.6M.
- Full-year 2024 IBSRELA net sales guidance raised to $140M-$150M.
- SG&A expenses $53.0M (+$26.2M YoY) due to commercialization of both products.
- Appointed Mike Kelliher as EVP Corporate Development and Strategy in March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024019986/0001628280-24-019986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024019986/ardx-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-019986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer